Kornelius Schulze

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

Tobias J. Weismüller, Palak Trivedi, Annika Bergquist et al. · Gastroenterology · 2017 · 523 citations · Full text

Medicine, Internal Medicine, Pathology +13

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein et al. · Journal of Hepatology · 2021 · 300 citations · Full text

Pharmacy, Immunology, Oncology +17

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

Jan Best, Lars P. Bechmann, Jan‐Peter Sowa et al. · Clinical Gastroenterology and Hepatology · 2019 · 289 citations

Medicine, Oncology, Pathology +17